Evidence map›Paper›PMID 37744404›Full record

ArticleiScience2023

Greta Volpedo, Thalia Pacheco-Fernandez, Timur Oljuskin, Hannah L Markle, Nazli Azodi, Shinjiro Hamano, Greg Matlashewski, Sreenivas Gannavaram, Hira L Nakhasi, Abhay R Satoskar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Frontiers in immunology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Greta VolpedoDepartment of Microbiology, The Ohio State University, Columbus, OH 43210, USA.
Thalia Pacheco-FernandezDepartment of Pathology, Wexner Medical Center, The Ohio State University, Columbus, OH 43210, USA.
Timur OljuskinDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Hannah L MarkleDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Nazli AzodiDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Shinjiro HamanoDepartment of Parasitology, Institute of Tropical Medicine (NEKKEN), The Joint Usage/Research Center on Tropical Disease, Nagasaki University, Nagasaki, Japan.
Greg MatlashewskiDepartment of Microbiology and Immunology, McGill University, Montreal, Canada.
Sreenivas GannavaramDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Hira L NakhasiDivision of Emerging and Transfusion Transmitted Diseases, CBER, FDA, Silver Spring, MD, USA.
Abhay R SatoskarDepartment of Microbiology, The Ohio State University, Columbus, OH 43210, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leishmaniasis is a tropical disease prevalent in 90 countries. Presently, there is no approved vaccine for human use. We developed a live attenuated

Indexed as

ImmunologyMetabolomicsParasitology

Identifiers

PMID37744404
PMCPMC10517399

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.